Virtual screening for cholesterol absorption inhibitors

Medicinal Chemistry

Volumn 11, Issue 1, 2015, Pages 2-12

  Sun, Lidan ^a   Qian, Hai ^a   Huang, Wenlong ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Cholesterol absorption inhibitors; Ezetimibe; NPC1L1; Virtual screening

Indexed keywords

AZETIDINONE DERIVATIVE; CHOLESTEROL; CHOLESTEROL ABSORPTION INHIBITOR; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYPOCHOLESTEROLEMIC AGENT; MEMBRANE PROTEIN; NIEMANN PICK C1 LIKE 1 PROTEIN; OXAZOLIDINONE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; COMPUTER AIDED DESIGN; DRUG SCREENING; HUMAN; MOLECULAR MODEL; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN STRUCTURE; STRUCTURE ACTIVITY RELATION;

EID: 84926429326     PISSN: 15734064     EISSN: 18756638     Source Type: Journal    
DOI: 10.2174/1573406410666140428152436     Document Type: Article

References (61)

1. Burnett, D. A. Beta-lactam cholesterol absorption inhibitors. Curr. Med. Chem., 2004, 11 (14), 1873-1887.
2. Maron, D. J.; Fazio, S.; Linton, M. F. Current perspectives on statins. Circulation, 2000, 101 (2), 207-213.
3. Van Heek, M.; Davis, H. Pharmacology of ezetimibe. Eur. Heart J. Suppl., 2002, 4 (suppl J), J5-J8.
4. Ge, L.; Wang, J.; Qi, W.; Miao, H.-H.; Cao, J.; Qu, Y.-X.; Li, B.-L.; Song, B.-L. The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-ind uced internalization of NPC1L1. Cell Metab., 2008, 7 (6), 508-519.
5. Weinglass, A. B.; Kohler, M.; Schulte, U.; Liu, J.; Nketiah, E. O.; Thomas, A.; Schmalhofer, W.; Williams, B.; Bildl, W.; McMasters, D. R. Extracellular loop C of NPC1L1 is important for binding to ezetimibe. Proc. Natl. Acad. Sci. U.S.A., 2008, 105 (32), 11140-11145.
6. Van Heek, M.; Farley, C.; Compton, D. S.; Hoos, L.; Alton, K. B.; Sybertz, E. J.; Davis, H. R. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Brit. J. Pharmacol., 2000, 129 (8), 1748-1754.
7. Stahura, F. L.; Bajorath, J. Virtual screening methods that complement HTS. Comb. Chem. High T. Scr., 2004, 7 (4), 259-269.
8. Willett, P. Similarity-based virtual screening using 2D fingerprints. Drug Discov. Today, 2006, 11 (23), 1046-1053.
9. Vaccaro, W. D.; Sher, R.; Davis, H. R. 2-Azetidinone cholesterol absorption inhibitors: I ncreased potency by substitution of the C-4 phenyl ring. Bioorg. Med. Chem., 1998, 6 (9), 1429-1437.
10. Rosenblum, S. B.; Huynh, T.; Afonso, A.; Davis Jr, H. R. Synthesis of 3-arylpropenyl, 3-a rylpropynyl and 3-arylpropyl 2-azetidinones as cholesterol absorption inhibitors: Application of the palladiumcatalyzed arylation of alkenes and alkynes. Tetrahedron, 2000, 56 (31), 5735-5742.
11. Burnett, D. A.; Caplen, M. A.; Browne, M. E.; Zhau, H.; Altmann, S. W.; Davis Jr, H. R.; Clader, J. W. Synthesis of fluorescent biochemical tools related to the 2-azetidinone class of cholesterol absorption inhibitors. Bioorg. Med. Che m. Lett., 2002, 12 (3), 315-318.
12. Wang, Y.; Zhang, H.; Huang, W.; Kong, J.; Zhou, J.; Zhang, B. 2-Azetidinone derivatives: Design, synthesis and evaluation of cholesterol absorpti on inhibitors. Eur. J. Med. Chem., 2009, 44 (4), 1638-1643.
13. Wang, Y.; Haiqian, W. H.; Zhang, H.; Zhou, J. Synthesis and biological evaluation of ezetimibe analogs as possible cholesterol abs orption inhibitors. Lett. Drug Des. Discov., 2011, 8 (6), 500-505.
14. Dugar, S.; Clader, J.; Burnett, D.; Browne, M.; Davis, H. Spirocycloalkyl-subst ituted azetidinones useful as hypocholesterolemic agents. W.O. Patent 1,994,017,038, August 4, 1994.
15. Alenfalk, S.; Dalströ m, M.; Hunegnaw, F.; Karlsson, S.; Lemurell, M.; Lindqvist, A.-M.; Skjä ret, T.; Starke, I. Diphenylazetidinone possessing cholesterol absorption inhibitory activity. W.O. Patent 2,005,061,451, July 7, 2005.
16. Alenfalk S. Dalström M. Hunegnaw F. Karlsson S. Lemurell M. Lindqvist A.-M. Skjä ret, T. Starke, I.Diphenylazetidinone possessing cholesterol absorption inhibitory activity, W.O. Patent 2,005,061,452, July 7 2005.
17. Alenfalk, S.; Dahlströ m, M.; Hunegnaw, F.; Karlsson, S.; Lemurell, M.; Lindqvist, A.-m.; Skjäret, T.; Starke, I. Diphenylazetidinone derivatives possessing cholesterol absorption inhi bitory activity. US Patent 7,871,998 B2, January 18, 2010.
18. Dahlströ m, M.; Karlsson, S.; Lemurell, M.; Nordberg, P.; Starke, I. New 2-azetidinone derivatives useful in the treatment of hyperl ipidaemic conditions. W.O. Patent 2,006,137,792A1, Decemble 28, 2006.
19. Kværnø , L.; Werder, M.; Hauser, H.; Carreira, E. M. Synthesis and in vitro evaluation of inhibitors of intestinal cholesterol absorption. J. Med. Chem., 2005, 48 (19), 6035-6053.
20. Altmann, S. W.; Burnett, D. A.; Davis Jr, H. R.; Graziano, M. P.; Laverty, M.; Yao, X., Use of azetidinone compounds. U.S. Patent 7,723,020 B2, May 25, 2003.
21. Jaehne, G.; Frick, W.; Flohr, S.; Lindenschmidt, A.; Glombik, H.; Kramer, W.; Heuer, H.; Schaefer, H.-L., Cationically substituted diph enylazetidinones, process for their preparation, medicaments comprising these compounds, and their use. U.S. Patent 7,176,194, February 13, 2007.
22. Glombik, H.; Krame, W.; Flohr, S.; Frick, W.; Heuer, H.; Jaehne, G.; Lindenschmidt, A.; Schä fer, H.-L., Diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use. U.S. Patent 6,992,067, January 31, 2006.
23. Xu, X.; Fu, R.; Chen, J.; Chen, S.; Bai, X. Ezetimibe analogs with a reorganized azetidinone ring: Design, synthesis, and evaluation of cholesterol absorption inhibitions. Bioorg. Med. Che m. Lett., 2007, 17 (1), 101-104.
24. Commons, T. J.; Laclair, C. M.; Strike, D. P., Tris carbamic acid esters: Inhibitors of cholesterol absorption; inhibitors of ACAT and CEH. E.P. Patent 0,635,501 A1, July 19, 1994.
25. Commons, T. J.; Laclair, C. M. 4-Carbamoyloxy-piperidine-1-carboxylic acid esters: Inhibitors of cholesterol absorption. W.O. Patent 1,995,034,539, December 21, 1995.
26. Betters, J. L.; Yu, L. NPC1L1 and cholesterol transport. FEBS Lett., 2010, 584 (13), 2740-2747.
27. Kwon, H. J.; Palnitkar, M.; Deisenhofer, J. The structure of the NPC1L1 N-terminal domain in a closed conformation. PloS One, 2011, 6 (4), e18722.
28. Davies, J. P.; Levy, B.; Ioannou, Y. A. Evidence for a Niemann-Pick C (NPC) gene family: Identification and characterization of NPC1L1. Genomics, 2000, 65 (2), 137-145.
29. Carstea, E. D.; Morris, J. A.; Coleman, K. G.; Loftus, S. K.; Zhang, D.; Cummings, C.; Gu, J.; Rosenfeld, M. A.; Pavan, W. J.; Krizman, D. B. Niemann-Pick C1 disease gene: Homology to mediators of cholesterol home ostasis. Science, 1997, 277 (5323), 228-231.
30. Loftus, S. K.; Morris, J. A.; Carstea, E. D.; Gu, J. Z.; Cummings, C.; Brown, A.; Ellison, J.; Ohno, K.; Rosenfeld, M. A.; Tagle, D. A. Murine model of Niemann-Pick C disease: Mutation in a cholesterol homeostasis gene. Science, 1997, 277 (5323), 232-235.
31. Altmann, S. W.; Davis, H. R.; Zhu, L.-j.; Yao, X.; Hoo s, L. M.; Tetzloff, G.; Iyer, S. P. N.; Maguire, M.; Golovko, A.; Zeng, M. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science, 2004, 303 (5661), 1201-1204.
32. Iyer, S. P. N.; Yao, X.; Crona, J. H.; Hoos, L. M.; Tetzloff, G.; Davis Jr, H. R.; Graziano, M. P.; Altmann, S. W. Characterization of the putative native and recombinant rat sterol transporter Niemann-Pick C1 Like 1 (NPC1L1) protein. BBA-Gen. Subjects, 2005, 1722 (3), 282-292.
33. Kwon, H. J.; Abi-Mosleh, L.; Wang, M. L.; Deisenhofer, J.; Goldstein, J. L.; Brown, M. S.; Infante, R. E. Structure of Nterminal domai n of NPC1 reveals distinct subdomains for binding and transfer of cholesterol. Cell, 2009, 137 (7), 1213-1224.
34. Betters, J.; Yu, L. Transporters as drug targets: Discovery and development of NPC1L1 inhibitors. Clin. Pharmacol. Ther., 2009, 87 (1), 117-121.
35. Kuwabara, P. E.; Labouesse, M. The sterol-sensing domain: Multiple families, a unique role? Trends Genet., 2002, 18 (4), 193-201.
36. Goldstein, J. L.; Brown, M. S. Regulation of the mevalonate pathway. Nature , 1990, 343 (6257), 425-430.
37. Brown M. S.Goldstein J. L. A proteolytic pathway that controls the cholesterol content of membranes cells, and blood. Proc. Natl. Acad. Sci. U.S.A. 1999 96 20 11041-11048.
38. Horton, J.; Goldstein, J.; Brown, M. In SREBPs: Transcriptional mediators of lipid homeostasis, Cold Spring Harbor symposia on quantitative biology, Cold Spring Harbor Laboratory Press: 2002; pp. 491-498.
39. Cooper, M. K.; Wassif, C. A.; Krakowiak, P. A.; Taipale, J.; Gong, R.; Kelley, R. I.; Porter, F. D.; Beachy, P. A. A defective response to Hedgehog signaling in disorders of cholesterol biosynthesis. Nat. Genet., 2003, 33 (4), 508-513.
40. Davis, H. R.; Zhu, L.-j.; Hoos, L. M.; Tetzloff, G.; Maguire, M.; Liu, J.; Yao, X.; Iyer, S. P. N.; Lam, M.-H.; Lund, E. G. Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of w hole-body cholesterol homeostasis. J. Biol. Chem., 2004, 279 (32), 33586-33592.
41. Hawes, B. E.; O'Neill, K. A.; Yao, X.; Crona, J. H.; Davis, H. R.; Graziano, M. P.; Altmann, S. W. In v ivo responsiveness to ezetimibe correlates with niemann-pick C1 like-1 (NPC1L1) binding affinity: Comparison of multiple species NPC1L1 orthologs. Mol. Pharmacol., 2007, 71 (1), 19-29.
42. Garcia-Calvo, M.; Lisnock, J.; Bull, H. G.; Hawes, B. E.; Burnett, D. A.; Braun, M. P.; Crona, J. H.; Davis, H. R.; Dean, D. C.; Detmers, P. A. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc. Natl. Acad. Sci. U.S.A., 2005, 102 (23), 8132-8137.
43. Yu, L.; Bharadwaj, S.; Brown, J. M.; Ma, Y.; Du, W.; Davis, M. A.; Michaely, P.; Liu, P.; Willingham, M. C. ; Rudel, L. L. Cholesterol-regulated translocation of NPC1L1 to the cell surface facilitates free cholesterol uptake. J. Biol. Chem., 2006, 281 (10), 6616-6624.
44. Brown, J.; Rudel, L.; Yu, L. NPC1L1 (Niemann-Pick C1-like 1) mediates sterol-specific unidirectional transport of non-esterified cholesterol in McArdle-RH7777 hepatoma cells. Biochem. J., 2007, 406, 273-283.
45. Yamanashi, Y.; Takada, T.; Suzuki, H. Niemann-Pick C1-like 1 overexpression facilitates ezetimibe-sensitive cholesterol and betasitosterol uptake in CaCo-2 cells. J. Pharmacol. Exp. Ther., 2007, 320 (2), 559-564.
46. Weinglass, A. B.; Kö hler, M. G.; Nketiah, E. O.; Liu, J.; Schmalhofer, W.; Thomas, A.; Williams, B.; Beers, L.; Smith, L.; Hafey, M. Madin-Darby canine kidney II cells: A pharmacologically valid ated system for NPC1L1-mediated cholesterol uptake. Mol. Pharmacol., 2008, 73 (4), 1072-1084.
47. Smart, E. J.; De Rose, R. A.; Farber, S. A. Annexin 2-caveolin 1 complex is a target of ezetimibe an d regulates intestinal cholesterol transport. Proc. Natl. Acad. Sci. U.S.A., 2004, 101 (10), 3450-3455.
48. KNIPFEL, M.; Davies, J. P.; Duong, P. T.; Kvaerno, L.; Carreira, E. M.; Phillips, M. C.; Hauser, H. Multiple plasma membrane receptors but not NPC1L1 mediate high-affinity, ezetimibesensitive cholesterol uptake into the intestinal brush border membrane. BBA-Mol. Cell Biol. L., 2007, 1771 (9), 1140-1147.
49. Cohen, J. C.; Pertsemlidis, A.; Fahmi, S.; Esmail, S.; Vega, G. L.; Grundy, S. M.; Hobbs, H. H. Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprote in levels. Proc. Natl. Acad. Sci. U.S.A., 2006, 103 (6), 1810-1815.
50. Wang, J.; Williams, C.; Hegele, R. Compound heterozygosity for two non-synonymous polymorphisms in NPC1L1 in a non-responder to ezetimibe. Clin. Genet., 2005, 67 (2), 175-177.
51. Wang, L.-J.; Wang, J.; Li, N.; Ge, L.; Li, B.-L.; Song, B.-L. Molecular characterization of the NPC1L1 variants identified from chol esterol low absorbers. J. Biol. Chem., 2011, 286 (9), 7397-7408.
52. Johnson, M. A.; Maggiora, G. M. Concepts and applications of molecular similarity. Wiley & Sons: New York, 1990.
53. Clader, J. W. The discovery of ezetimibe: A view from outside the receptor. J. Med. Chem., 2004, 47 (1), 1-9.
54. Bender, A.; Glen, R. C. Molecular similarity: A key technique in molecular informatics. Org. Biomol. Chem., 2004, 2 (22), 3204-3218.
55. Maldonado, A. G.; Doucet, J.; Petitjean, M.; Fan, B.-T. Molecular similarity and diversity in chemoinformatics: From theory to appli cations. Mol. Divers., 2006, 10 (1), 39-79.
56. Rush, T. S.; Grant, J. A.; Mosyak, L.; Nicholls, A. A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction. J. Med. Chem., 2005, 48 (5), 1489-1495.
57. Yang, L.; Berk, S. C. ; Rohrer, S. P.; Mosley, R. T.; Guo, L.; Underwood, D. J.; Arison, B. H.; Birzin, E. T.; Hayes, E. C.; Mitra, S. W. Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2. Proc. Natl. Acad. Sci. U.S.A., 1998, 95 (18), 10836-10841.
58. McMasters D. R. Garcia-Calvo M. Maiorov V. McCann M. E. Meurer R. D. Bull H. G. Lisnock J. Howell K. L. DeVita, R. J. Spiroimidazolidinone NPC1L1 inhibitors. 1: Discovery by 3Dsimilarity-based virtual screening. Bioorg. Med. Chem. Lett. 2009 19 (11) 2965-2968.
59. Kearsley, S. K.; Sallamack, S.; Fluder, E. M.; Andose, J. D.; Mosley, R. T.; Sheridan, R. P. Chemical similarity using physiochemical property descriptors. J. Chem. Inf. Comp. Sci., 1996, 36 (1), 118-127.
60. Howell, K. L. ; DeVita, R. J.; Garcia-Calvo, M.; Meurer, R. D.; Lisnock, J.; Bull, H. G.; McMasters, D. R.; McCann, M. E.; Mills, S. G. Spiroimidazolidinone NPC1L1 inhibitors. Part 2: Structure-activity studies and in vivo efficacy. Bioorg. Med. Chem. Lett., 2010, 20 (23), 6929-6932.
61. Zhu, X.; Ji, J.; Huang, D.; Zhu, Y.; Tang, C.; Yang, X.; Qian, H.; Huang, W. Discovery, Synthesis and Evaluation of Novel Chol esterol Absorption Inhibitors. Chem. Biol. Drug Des., 2012, 80 (3), 426-433